{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:49:11Z","timestamp":1726505351965},"reference-count":19,"publisher":"California Digital Library (CDL)","issue":"3","license":[{"start":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T00:00:00Z","timestamp":1585612800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["WestJEM"],"DOI":"10.5811\/westjem.2020.3.47328","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T21:28:22Z","timestamp":1585949302000},"source":"Crossref","is-referenced-by-count":1,"title":["Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department"],"prefix":"10.5811","volume":"21","author":[{"given":"Cortlyn","family":"Brown","sequence":"first","affiliation":[{"name":"University of California San Francisco, Department of Emergency Medicine, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeanne","family":"Noble","sequence":"additional","affiliation":[{"name":"University of California San Francisco, Department of Emergency Medicine, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatan","family":"Coralic","sequence":"additional","affiliation":[{"name":"University of California San Francisco School of Pharmacy, San Francisco, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"29705","published-online":{"date-parts":[[2020,3,31]]},"reference":[{"key":"ref0","unstructured":"1. \tCoronavirus Disease 2019 (COVID-19) in the U.S. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/cases-in-us.html. Published March 13, 2020. Accessed March 13, 2020."},{"key":"ref1","unstructured":"2. \tNIH clinical trial of investigational vaccine for COVID-19 begins. Available at: https:\/\/www.nih.gov\/news-events\/news-releases\/nih-clinical-trial-investigational-vaccine-covid-19-begins. Published March 16, 2020. Accessed March 18, 2020."},{"key":"ref2","unstructured":"3. \tLexi-Drugs Online. Available at: https:\/\/www.wolterskluwercdi.com\/lexicomp-online\/. Published 2020. Accessed March 23, 2020."},{"key":"ref3","unstructured":"4. \tTakeda Initiates Development of a Plasma-Derived Therapy for COVID-19. Available at: https:\/\/www.takeda.com\/newsroom\/newsreleases\/2020\/takeda-initiates-development-of-a-plasma-derived-therapy-for-covid-19\/. Published March 4, 2020. Accessed March 14, 2020."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5. \tHung IF, To KK, Lee C-K, et al. Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clin Infect Dis. 2011;52(4):447-56.","DOI":"10.1093\/cid\/ciq106"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. \tCheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.","DOI":"10.1007\/s10096-004-1271-9"},{"key":"ref6","unstructured":"7. \tChina puts 245 COVID-19 patients on convalescent plasma therapy. Xinhua. Available at: http:\/\/www.xinhuanet.com\/english\/2020-02\/28\/c_138828177.htm. Published February 28, 2020. Accessed March 23, 2020."},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. \tHoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. March 2020. In Press.","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9. \tCasadevall A, Pirofski L. The convalescent sera option for containing COVID-19. J Clin Invest. March 2020. In Press.","DOI":"10.1172\/JCI138003"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. \tZumla A, Chan JFW, Azhar EI, et al. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327-47.","DOI":"10.1038\/nrd.2015.37"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. \tWang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.","DOI":"10.1038\/s41422-020-0282-0"},{"key":"ref11","unstructured":"12. \tGilead. Available at: https:\/\/rdvcu.gilead.com. Accessed March 18, 2020."},{"key":"ref12","unstructured":"13. \tMan dies after ingesting chloroquine in an attempt to prevent coronavirus. Available at: https:\/\/www.nbcnews.com\/health\/health-news\/man-dies-after-ingesting-chloroquine-attempt-prevent-coronavirus-n1167166. Accessed March 24, 2020."},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. \tGao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. February 2020. In Press.","DOI":"10.5582\/bst.2020.01047"},{"key":"ref14","unstructured":"15. \tAudio transcript of the news briefing held by the State Council of China on February 17, 2020. The National Health Commission of the People\u2019s Republic of China. February 2020. Available at: http:\/\/www.nhc.gov.cn\/xcs\/yqfkdt\/202002\/f12a62d10c2a4 8c6895cedf2faea6e1f.shtml. Accessed March 24, 2020."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. \tYao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. March 2020. In Press.","DOI":"10.1093\/cid\/ciaa237"},{"key":"ref16","unstructured":"17. \tJun C, Danping L, Ping L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ (Med Sci). 2020;49."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. \tGautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents. March 2020. In Press.","DOI":"10.1101\/2020.03.22.20040949"},{"key":"ref18","unstructured":"19. \tCao B, Wang Y, Wen D, et al. A Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. March 2020. In Press."}],"container-title":["Western Journal of Emergency Medicine"],"original-title":[],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T21:28:29Z","timestamp":1585949309000},"score":1,"resource":{"primary":{"URL":"https:\/\/escholarship.org\/uc\/item\/622689zd"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,31]]},"references-count":19,"issue-title":["WestJEM 21.3 May Issue"],"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.5811\/westjem.2020.3.47328","relation":{},"ISSN":["1936-900X"],"issn-type":[{"type":"print","value":"1936-900X"}],"subject":[],"published":{"date-parts":[[2020,3,31]]}}}